NASDAQ$ORGO
Organogenesis Holdings Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported a decrease in revenue and net income compared to the same quarter last year, and withdrew fiscal year 2023 guidance due to uncertainty related to recent local coverage determinations.
Organogenesis Holdings Inc. reported second quarter 2023 financial results with a decrease in net revenue to $117.3 million compared to $121.4 million for the second quarter of 2022. Net income also decreased to $5.3 million from $8.7 million in the prior year. The company withdrew its fiscal year 2023 guidance due to uncertainties from recent local coverage determinations.
- Net revenue for the second quarter of 2023 was $117.3 million, a decrease of $4.1 million compared to the second quarter of 2022.
- Advanced Wound Care products revenue was $110.1 million, a 3% decrease from the second quarter of 2022.
- Surgical & Sports Medicine products revenue was $7.2 million, a 5% decrease from the second quarter of 2022.
- Net income for the second quarter of 2023 was $5.3 million, compared to $8.7 million for the second quarter of 2022.
Headline financials
Revenue & EPS history
Organogenesis · Revenue · Quarterly
$117M
Revenue by segment
Organogenesis · $117M total across 2 segments · Q2 2023
- Advanced Wound Care$110M-3.3%93.8%
- Surgical & Sports Medicine$7.24M-4.7%6.2%
Forward guidance
The Company is withdrawing its previously announced fiscal year 2023 guidance due to the uncertainty resulting from the potential impact of the recently published local coverage determinations from Novitas, First Coast Services and CGS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+2.8%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+0.5%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+102.3%
Q4 2024
Best reaction
-42.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -6.2% | -5.9% | |
| Q4 2025 | -13.8% | -22.4% | -38.1% | |
| Q3 2025 | +44.1% | +66.6% | +21.9% | |
| Q1 2025 | -42.4% | -43.6% | -43.3% | |
| Q4 2024 | +102.3% | +95.8% | +46.6% | |
| Q3 2024 | +26.6% | +10.3% | +0.9% | |
| Q2 2024 | +2.0% | +6.4% | -1.2% | |
| Q1 2024 | +31.2% | +23.2% | +19.0% | |
| Q4 2023 | -16.3% | -20.3% | -18.6% | |
| Q3 2023 | +6.8% | +22.9% | +62.4% | |
| Q2 2023 | -25.7% | -27.0% | -31.6% | |
| Q1 2023 | +29.7% | +43.2% | +81.1% | |
| Q4 2022 | +11.0% | -2.9% | -13.1% | |
| Q3 2022 | -18.3% | -11.5% | -17.7% | |
| Q2 2022 | -25.2% | -26.6% | -44.0% | |
| Q1 2022 | +4.6% | +9.8% | -9.3% | |
| Q4 2021 | +18.1% | +15.6% | +2.4% | |
| Q3 2021 | -6.4% | -5.0% | -16.1% | |
| Q2 2021 | +1.9% | +2.5% | +8.2% | |
| Q1 2021 | -15.3% | -11.3% | -28.7% | |
| Q4 2020 | +3.8% | +8.5% | +31.4% | |
| Q3 2020 | +8.2% | +5.2% | +20.2% | |
| Q2 2020 | +0.7% | +1.5% | +3.2% | |
| Q1 2020 | -9.9% | -18.8% | +4.2% | |
| Q4 2019 | -16.2% | +11.6% | +23.5% | |
| Q3 2019 | +10.3% | +8.8% | -36.1% | |
| Q2 2019 | -4.7% | -10.8% | +26.5% | |
| Q1 2019 | -0.4% | +1.0% | +0.7% | |
| Q4 2018 | -3.0% | -5.3% | -16.8% | |
| Q4 2017 | -3.0% | -5.3% | -16.8% | |
| Q2 2018 | +0.3% | +0.2% | +0.1% | |
| Q1 2018 | +0.0% | +0.4% | +0.3% | |
| Q3 2017 | +0.1% | +0.1% | -1.0% | |
| Q2 2017 | +0.0% | +0.1% | +1.5% | |
| Q1 2017 | -0.3% | -0.3% | +0.5% | |
| Q4 2016 | +0.0% | +0.0% | +0.0% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro